Lobe Sciences to Present at Virtual One2One Investor Forum
Vancouver, British Columbia–(Newsfile Corp. – February 22, 2021) – Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) announces that Philip Young, CEO and Director, will be interviewed on Tuesday, February 23rd, 2021 at 1:00 pm EST by broadcast journalist Christine Corrado of Proactive Investors, a leading multi-media news organization, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt, and London.
The Virtual One2One Investor Forum invitation will be sent to Proactive’s 20,000 YouTube subscribers and will be broadcasted internationally. The audience will consist of high-net-worth investors, fund managers, private client brokers and analysts. Lobe’s presentation will be followed by a Q&A session and it will be published online.
Recent Company highlights & topics to be discussed include:
The successful completion and testing of the proof-of-concept prototype of its proprietary nasal mist device
Pre-clinical study of psilocybin plus NAC for treatment of PTSD and mTBI with the University of Miami
The appointment of Philip Young as CEO and Director
The closing of an upsized $3,445,847 non-brokered private placement
The appointment of Jonathan Gilbert as Executive Chairman
Executed LOI for CAD$23 million sale of certain assets related to Cowlitz County Cannabis Cultivation Inc.
About Lobe Sciences Ltd.
Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.